JP2012255007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012255007A5
JP2012255007A5 JP2012176112A JP2012176112A JP2012255007A5 JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5 JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5
Authority
JP
Japan
Prior art keywords
mutein
amino acid
acid sequence
peg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012176112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012255007A (ja
JP5774557B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012255007A publication Critical patent/JP2012255007A/ja
Publication of JP2012255007A5 publication Critical patent/JP2012255007A5/ja
Application granted granted Critical
Publication of JP5774557B2 publication Critical patent/JP5774557B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012176112A 2009-08-05 2012-08-08 リポカリン突然変異タンパク質の制御放出製剤 Expired - Fee Related JP5774557B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23136509P 2009-08-05 2009-08-05
US61/231,365 2009-08-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012523344A Division JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤

Publications (3)

Publication Number Publication Date
JP2012255007A JP2012255007A (ja) 2012-12-27
JP2012255007A5 true JP2012255007A5 (enExample) 2013-09-26
JP5774557B2 JP5774557B2 (ja) 2015-09-09

Family

ID=43531164

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523344A Pending JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤
JP2012176112A Expired - Fee Related JP5774557B2 (ja) 2009-08-05 2012-08-08 リポカリン突然変異タンパク質の制御放出製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012523344A Pending JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤

Country Status (11)

Country Link
US (1) US20120201873A1 (enExample)
EP (2) EP2461800A2 (enExample)
JP (2) JP2013501033A (enExample)
KR (1) KR20120099371A (enExample)
CN (2) CN106139123A (enExample)
AU (2) AU2010280688A1 (enExample)
BR (1) BR112012002709A2 (enExample)
CA (1) CA2770149A1 (enExample)
IN (1) IN2012DN00407A (enExample)
RU (1) RU2012107812A (enExample)
WO (1) WO2011015634A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9273116B2 (en) * 2011-02-28 2016-03-01 Korea University Research And Business Foundation Fusion protein comprising albumin and retinol-binding protein
US10064915B2 (en) 2011-02-28 2018-09-04 Korea University Research And Business Foundation Fusion protein comprising albumin and retinol-binding protein
US9701732B2 (en) 2011-02-28 2017-07-11 Korea University Research And Business Foundation Fusion protein comprising albumin and retinol-binding protein
US9415012B2 (en) * 2011-06-14 2016-08-16 Ipsen Pharma S.A.S. Sustained-release composition containing peptides as active ingredient
WO2013068590A1 (en) * 2011-11-11 2013-05-16 Pieris Ag Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization
WO2013104586A1 (en) * 2012-01-09 2013-07-18 Pieris Ag Methods for preventing, treating or diagnosing disorders
JP6184982B2 (ja) 2012-02-02 2017-08-23 エスバテック − ア ノバルティス カンパニー エルエルシー 点眼用抗体含有徐放性製剤
WO2013138346A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
HK1206270A1 (en) 2012-03-16 2016-01-08 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN103394094B (zh) * 2013-07-16 2015-05-13 天津大学 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法
CN103360609B (zh) * 2013-07-16 2015-08-19 天津大学 一种双亲性的蛋白质-高分子键合体及其制备方法
CA2936611A1 (en) 2014-01-13 2015-07-16 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
EP3250184B1 (en) 2015-01-27 2024-12-18 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
EP4378962A3 (en) 2015-05-04 2024-07-31 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
CA3014406A1 (en) * 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia,and hormone-related tumors
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
EP1087778B1 (en) 1998-06-08 2005-10-26 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
NZ518143A (en) 1999-10-08 2004-04-30 Nektar Therapeutics Al Corp Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
DK2599502T3 (en) 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
CN102935069A (zh) * 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
EP1656115A4 (en) * 2003-07-23 2009-07-08 Pr Pharmaceuticals COMPOSITIONS WITH CONTROLLED RELEASE
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス, インコーポレイテッド タンパク様薬剤およびその使用
US8598317B2 (en) * 2006-03-20 2013-12-03 Technische Universitaet Muenchen Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
DE602007009995D1 (de) * 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
US8178483B2 (en) * 2007-03-30 2012-05-15 Colgate-Palmolive Company Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
EP2142293A2 (de) * 2007-04-26 2010-01-13 Basf Se Enzymatisches verfahren zur herstellung von mikrokapseln
PL2170287T3 (pl) * 2007-07-26 2014-04-30 Aqtis Ip Bv Mikrocząstki zawierające PCL i ich zastosowania
CA2711984A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
CN106986926A (zh) * 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase

Similar Documents

Publication Publication Date Title
JP2012255007A5 (enExample)
WO2013096901A8 (en) Pharmaceutical formulations for fumagillin derivative-phf conjugates
EP3406347A3 (en) Xten conjugate compositions and methods of making same
MX368966B (es) Conjugados de proteina-polimero-farmaco.
WO2010033220A3 (en) Modified therapeutics peptides, methods of their preparation and use
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
JP2018015005A5 (enExample)
JP2013519636A5 (enExample)
JP2010215657A5 (enExample)
UA114709C2 (uk) Кон'югат, що містить похідну оксинтомодуліну, fc-ділянку імуноглобуліну та непептидильний полімер, та його застосування
MX2023010178A (es) Conjugados de anticuerpo farmaco anti-cd70.
UA111820C2 (uk) Модифікований зв'язуючий протеїн, що інгібує взаємодію vegf-а-рецептора
JP2012509902A5 (enExample)
JP2010534486A5 (enExample)
JP2014129395A5 (enExample)
JP2013507132A5 (enExample)
BR112014003240A2 (pt) composição de prostaciclina com liberação sustentada
JP2010202664A5 (enExample)
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
EP2621480A4 (en) CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY
HK1209045A1 (en) Pegylated oxm variants
JP2011515499A5 (enExample)
WO2010064252A3 (en) Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
JP2017523781A5 (enExample)